Relay Therapeutics Announces Initial Clinical Data Demonstra

Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at... | April 18, 2023

Related Keywords

United States , American , Caroline Glen , Don Bergstrom , Nasdaq , Exchange Commission , Relay Therapeutics Inc , American Association For Cancer Research , Relay Therapeutics , American Association , Cancer Research , Annual Meeting , Human Trial , Mutations Represented , Enrolled Patients , Target Exposure , Inhibition Achieved , Inhibition Demonstrated , Safety Analysis Supports , Meaningfully Differentiated , Response Achieved , Breast Cancer Patient , Response Evaluation Criteria , Solid Tumors , Anti Tumor Activity Observed , Breast Cancer Patients Across Range , Relay Therapeutic , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Nc Stock Exchange , News , Information , Press Release , Multiple , Doses , Chieved , Sustained , Target , Exposure , F , Mutant , Inhibition , O , Rade , , Cash , Dr , Diarrhea , Bserved , It , Exposures , Favorable , Nitial , Safety , Rofile Rlay Us75943r1023 ,